A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate SHR3680 combined with Docetaxel to improve Metastatic
Castration Resistant Prostate Cancer Patients whether the patient's Time to prostate specific
antigen (PSA) progression is superior to SHR3680 or Docetaxel single drug.